PATENT CLAIM ANALYSIS

Application Number: 16316714
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-09
Patent Classification: ["548", "364100"]

Abstract:
The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

Claim (Index 35):
The method of  claim 34 , wherein the anti-PD-1 antibody is nivolumab.

Metadata:
- Claim Count in Document: 22.0
- Percentile: 99.0
- Lexical Diversity: 1.43333
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14977709', '14072563', '14819541', '14339123', '14820611']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7623323178522289
- 35 USC 102 Novelty (BERT): 0.5142022531746119
- Combined Prediction Score: 0.7375193113844671
- Mean Citation Score: 280.301294
- Max Citation Score: 286.54965
- Similarity Product: 188.51578140864368

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test